Update on Diagnosis and Treatment of Diabetic Retinopathy: A Consensus Guideline of the Working Group of Ocular Health (Spanish Society of Diabetes and Spanish Vitreous and Retina Society)
Table 3
Recommended ophthalmological controls in patients with DR according to stage and complications.
DR stage
Control periodicity
Nonproliferative diabetic retinopathy (NPDR)
Mild
Diabetic macular edema (DME)
Present
(i) Non-CIDME
Every 6 months
(ii) CIDME
Every 1–4 months
Absent
Every 12 months
Moderate
Diabetic macular edema (DME)
Present
(i) Non-CIDME
Every 3-4 months
(ii) CIDME
Every 1–4 months
Absent
Every 6–12 months
Severe
Diabetic macular edema (DME)
Present
(i) Non-CIDME
Every 3-4 months
(ii) CIDME
Every 1–4 months
Absent
Every 6 months
Proliferative diabetes retinopathy (PDR)
Every 3 months
In addition to optimizing blood glucose levels, lipid profile, and blood pressure. In this case, intraocular treatment with anti-VEGF is recommended as first-line therapy for most eyes.
